Solid-state stability of spray-dried insulin powder for inhalation: chemical kinetics and structural relaxation modeling of exubera above and below the glass transition temperature

Journal of Pharmaceutical Sciences

Volumn 99, Issue 9, 2010, Pages 3698-3710

  Sadrzadeh, Negar ^a,c   Miller, Danforth P ^a,d   Lechuga Ballesteros, David ^a,e   Harper, Nancy J ^b   Stevenson, Cynthia L ^a,c   Bennett, David B ^a,f  

^a NEKTAR THERAPEUTICS   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c Novartis Pharmaceuticals ^*  (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Aridis Pharmaceuticals   (United States)

^f NeurogesX Inc   (United States)

Author keywords

Amorphous; Degradation kinetics; Insulin; Spray drying; Structural relaxation

Indexed keywords

RECOMBINANT HUMAN INSULIN;

ARTICLE; DRUG STABILITY; DRUG STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; GLASS TRANSITION TEMPERATURE; INHALATION; KINETICS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOLID STATE; TEMPERATURE SENSITIVITY;

EID: 77956370334     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21936     Document Type: Article

References (47)

1. Manning MC, Patel K, Borchardt RT. 1989. Stability of protein pharmaceuticals. Pharm Res 6:903-918.
2. Pearlman R, Nguyen TH. 1992. Pharmaceutics of protein drugs. J Pharm Pharmacol 44:178-185.
3. Pikal MJ. 1994. Freeze-drying of proteins: Process formulation and stability. In: Cleland JL, Langer R, editors. Formulation and delivery of proteins and peptides. Washington, DC: American Chemical Society. pp. 120-133.
4. Wang YCJ, Hanson MA. 1998. Parenteral formulations of proteins and peptides: Stability and stabilizers. J Parenteral Sci Technol 42:S1-S24.
5. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
6. Carpenter JF, Pikal MJ, Randolph TW. 1997. Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14:969-975.
7. Skrabanja ATP, De Meere ALJ, De Ruiter RA, Van Den Oetelaar JM. 1994. Lyophilization of biotechnology products. J Pharm Sci Technol 48:311-317.
8. Pikal MJ. 1990. Freeze-drying of proteins. Part I: Process design. BioPharm 3:18-20, 22-24, 26-28.
9. Lee G. 2002. Spray-drying of proteins. Pharm Biotechnol 13:135-138.
10. Broadhead J, Rouan SKE, Rhodes CT. 1992. The spray drying of pharmaceuticals. Drug Dev Ind Pharm 18:1169-1206.
11. Sonner C, Maa YF, Lee G. 2002. Spray-freeze drying for protein and powder preparation: Particle characterization and a case study with trypsinogen stability. J Pharm Sci 91:2122-2139.
12. Maa YF. 1999. Protein inhalation powders: Spray drying vs. spray freeze drying. Pharm Res 16:249-254.
13. Platz RM, Patton JS, Foster L, Eljamal M. 1996. Pulmonary delivery of aerosolized medicaments. PCT, WO 96/32149.
14. Brange J. 1994. Stability of insulin: Studies on the physical and chemical stability of insulin in pharmaceutical formulation. Boston, MA: Kluwer Academic Publishers.
15. Brange J, Langkjaer L, Havelund S, Volund A. 1992. Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm Res 9:715-726.
16. Darrington RT, Anderson BD. 1994. The role of intramolecular nucleophilic catalysis and the effects of self-association on the deamidation of human insulin at low pH. Pharm Res 11:784-793.
17. Darrington RT, Anderson BD. 1995. Effects of insulin concentration and self-association of its A-21 cyclic anhydride intermediate to desamido insulin and covalent dimer. Pharm Res 12:1077-1084.
18. Darrington RT, Anderson BD. 1995. Evidence for a common intermediate in insulin deamidation and covalent dimer formation: Effects of pH and aniline trapping in dilute acidic solution. J Pharm Sci 84: 275-282.
19. Brange J, Havelund S, Hougaard P. 1992. Chemical stability of insulin. 2. Formation of high molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res 9:727-734.
20. Strickley RG, Anderson BD. 1996. Solid-state stability of human insulin. I. Mechanism and the effect of water on the kinetics of degradation in lyophilizes from pH 2-5 solutions. Pharm Res 13:1142-1153.
21. Strickley RG, Anderson BD. 1997. Solid-state stability of human insulin. II. Effect of water on reactive intermediate portioning in lyophiles from pH 2-5 solutions: Stabilization against covalent dimer formation. J Pharm Sci 86:645-653.
22. Pikal MJ, Rigsbee RD. 1997. The stability of insulin in crystalline and amorphous solids: Observation of greater stability for the amorphous form. Pharm Res 14:1379-1387.
23. Duddu SP, Weller K. 1996. Importance of glass transition temperature in accelerated stability testing of amorphous solids: Case study using lyophilized aspirin formulation. J Pharm Sci 85:345-347.
24. Shamblin SL, Hancock BC, Pikal MJ. 2006. Coupling between chemical reactivity and structural relaxation in pharmaceutical glasses. Pharm Res, 10:2254-2268.
25. Chang L, Shepherd D, Sun J, Ouellette D, Grant KL, Tang X, Pikal MJ. 2005. Mechanism of protein stabilization by sugars during freeze-drying and storage: Native structure preservation, specific interaction and/or immobilization in a glassy matrix? J Pharm Sci 94:1427-1444.
26. Guo Y, Byrn SR, Zografi G. 2000. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci 89:128-143. (Pubitemid 30080161)
27. Ghandhi J. 2004. Spray drying fine powders for pulmonary drug delivery - Successes and challenges. Presentation at the American Institute of Chemical Engineers Annual Meeting, Austin, TX.
28. USP, Insulin Human, Monograph.
29. Kohlrausch F. 1863. Ueber de Elastische Nachwirkung Beider Torsion. Pogg Ann Phys 119:337-368.
30. Williams G, Watts DC. 1970. Non-symmetrical dielectric relaxation behavior arising from a simple decay function. Trans Faraday Soc 66:80-85.
31. Yoshioka S, Aso Y, Kojima S. 2001. Usefulness of the Kohlrausch-Williams- Watts stretched exponential function to describe protein aggregation in lyophilized formulations and the temperature dependence near the glass transition temperature. Pharm Res 18:256-260.
32. Bohmer R, Ngai KL, Angell CA, Plazek DJ. 1993. Non-exponential relaxations in strong and fragile glass-formers. J Chem Phys 99:4201-4209.
33. Kawakami K, Pikal MJ. 2005. Calorimetric investigation of the structural relaxation of amorphous materials: Evaluating validity of the methodologies. J Pharm Sci 94:948-965.
34. Liu J, Rigsbee DR, Stotz C, Pikal MJ. 2002. Dynamics of pharmaceutical amorphous solids: The study of enthalpy relaxation by isothermal microcalorimetry. J Pharm Sci 91:1853-1862. (Pubitemid 34810530)
35. Peyron M, Pierens GK, Lucas AJ, Hall LD, Stewart RC. 1996. The modified stretched-exponential model for characterization of NMR relaxation in porous media. J Magn Reson Ser A 118:214-220.
36. Brange J. 1992. Chemical stability of insulin. 4. Mechanisms and kinetics of chemical transformations in pharmaceutical formulation. Acta Pharm Nordica 4:209-222.
37. Bhatt NP, Patel K, Borchardt RT. 1990. Chemical pathways of peptide degradation. I. Deamidation of adrenocorticotropic hormone. Pharm Res 7:593-599.
38. Mehrer H. 2007. Diffusion in Solids. Berlin, Heidelberg, New York: Springer. p. 127.
39. Taylor R. 1997. An introduction to error analysis. 2nd edition. Sausalito California: University Science Books.
40. Yoshioka SY, Aso Y, Kojima S. 2004. Temperature and glass transition temperature-dependence of bimolecular reaction rates in lyophilized formulations described by the Adam-Gibbs-Vogel equation. J Pharm Sci 93:1062-1069.
41. Roy ML, Pikal MJ, Rickard EC, Maloney AM. 1991. The effects of formulation and moisture on the stability of a freeze-dried monoclonal antibody-VINCA conjugate: A test of the WLF glass transition theory. International Symposium on Biological Product Freeze-Drying and Formulation, Vol. 74, pp. 323-340.
42. Pikal MJ. 2004. Mechanisms of protein stabilization during freeze-drying and storage: The relative importance of thermodynamic stabilization and glassy state relaxation dynamics. In: Rey L, May JC, editors. Freeze-drying/ lyophilization of pharmaceutical and biological products. New York: Marcel Dekker. pp. 63-107.
43. Yoshioka S, Miyazaki T, Aso Y. 2006. Degradation rate of lyophilized insulin, exhibiting an apparent Arrhenius behavior around glass transition temperature regardless of significant contribution of molecular mobility. J Pharm Sci 95:2684-2691. (Pubitemid 46093175)
44. Yoshioka S, Aso Y, Miyazaki T. 2006. Negligible contribution of molecular mobility to the degradation rate of insulin lyophilized with poly(vinylpyrrolidine). J Pharm Sci 95:939-943.
45. Yoshioka S, Miyazaki T, Aso Y. 2006. b-Relaxation of insulin molecule in lyophilized formulations containing trehalose or dextran as a determinant of chemical reactivity. Pharm Res 23:961-966.
46. Yoshioka S, Aso Y. 2005. A quantitative assessment of the significance of molecular mobility as a determinant for the stability of lyophilized insulin formulations. Pharm Res 22:1358-1364. (Pubitemid 41176040)
47. Constantino HR, Langer R, Klibanov AM. 1994. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J Pharm Sci 83: 1662-1669.